Navigating US Inflation Reduction Act Incentives for Domestic API Manufacturing Supplies

What are the key provisions of the Inflation Reduction Act that affect API manufacturers?

The Inflation Reduction Act of 2022 introduced a Domestic Content Tax Credit (DCTC) aimed at encouraging the production of high‑value goods, including active pharmaceutical ingredients (APIs), within the United States. The credit can be claimed at a rate of up to 30 % of the qualified investment in eligible property, with a maximum of US$7,500 per employee for each qualifying project. To qualify, at least 40 % of the property’s cost must be domestic content, measured by the proportion of components sourced from US‑based manufacturers or those meeting the Treasury’s domestic‑content definition. The credit applies to property placed in service after 1 January 2023 and is claimed on the corporate income‑tax return (Form 1120) for the year the property becomes operational.

How can API manufacturers qualify for the domestic content tax credit?

Eligibility is determined by three core criteria:

1. Qualified Property – The asset must be used in the manufacturing, processing, or assembly of APIs, or in the production of equipment directly supporting those processes. Property such as reactors, filtration systems, and analytical instruments (e.g., HPLC, NMR) can qualify if they meet the domestic‑content threshold.
2. Domestic Content Threshold – At least 40 % of the total cost of the property must be attributable to components that are either manufactured in the United States or sourced from a US‑based supplier that complies with the Treasury’s domestic‑content rules. Documentation of each component’s origin is required.
3. Timing – The property must be placed in service after 1 January 2023. Retroactive claims are not permitted, and the credit must be claimed in the tax year the asset becomes operational.

The Treasury’s guidance clarifies that the domestic‑content calculation can be performed using either a cost‑based method (summing the cost of qualifying US‑sourced components) or a percentage‑based method (applying a fixed domestic‑content factor to the total cost). Companies may choose the method that yields the higher credit, but the chosen method must be consistently applied across all assets within the same project.

What documentation and compliance steps are required under the IRA?

The IRS and Treasury have issued detailed notice requirements to substantiate DCTC claims. The following documentation is typically required:

• Purchase Orders and Invoices – Original invoices showing the supplier’s location, part numbers, and cost breakdown for each component.
• Certificates of Origin – Supplier‑issued statements confirming that the component was manufactured in the United States, often accompanied by a Form 3520‑S for customs‑bonded goods.
• Cost Allocation Worksheets – Internal calculations demonstrating how the domestic‑content percentage was derived, including any allocation of shared costs (e.g., engineering services).
• Asset Register – A detailed register of all qualified property, including serial numbers, dates placed in service, and the specific use within API production.
• Form 8916 – The IRS form used to claim the DCTC, which must be filed with the corporate tax return. Supporting schedules must be attached, summarising the total qualified investment and the domestic‑content percentage.

Compliance audits are expected to focus on the traceability of component origins. Companies should retain all supporting documents for at least five years after the tax year in which the credit is claimed, as stipulated by IRS record‑keeping rules.

Which US states offer additional incentives that complement the IRA?

Several states have introduced their own programmes to augment the federal DCTC, often targeting the pharmaceutical sector directly. Notable examples include:

• Massachusetts – Offers a Manufacturing Investment Tax Credit of up to 6 % of qualified capital expenditures for life‑science facilities, with an additional Workforce Development Grant for training programmes.
• North Carolina – Provides a Job Development Investment Grant (JDIG) that can cover up to 50 % of a project’s capital costs, subject to a cap of US$5 million per project.
• Texas – Operates the Texas Enterprise Fund, which can award cash incentives ranging from US$5 million to US$25 million for large‑scale manufacturing projects that create a minimum of 100 jobs.

When planning a new API facility, it is advisable to map the federal DCTC against state‑level incentives to maximise total tax relief. Coordination with state economic‑development agencies early in the project lifecycle can streamline application timelines and avoid duplication of documentation.

How does the IRA impact supply‑chain planning for biotech and pharma companies?

The introduction of the DCTC has prompted many organisations to reassess their sourcing strategies. Key considerations include:

• Supplier Localisation – Companies are increasingly qualifying US‑based suppliers or encouraging existing overseas partners to establish US subsidiaries to meet the domestic‑content threshold.
• Inventory Management – To avoid delays in credit eligibility, firms must align component deliveries with the asset’s placement‑in‑service schedule, ensuring that all qualifying parts are on‑site before the commissioning date.
• Cost‑Benefit Analysis – While the credit can offset up to 30 % of investment, the additional administrative burden and potential premium for US‑sourced components must be weighed against the tax benefit. A typical analysis shows a net benefit of approximately US$1.2 million per US$10 million of qualified investment, assuming a 30 % credit and a 40 % domestic‑content mix.
• Risk Management – Companies should monitor legislative updates, as the Treasury may adjust the domestic‑content definition or credit rates in future fiscal years. Maintaining a flexible procurement strategy helps mitigate the risk of regulatory changes.

Molekula’s catalogue of high‑purity reagents and custom‑synthesis services includes a range of US‑manufactured API intermediates, facilitating compliance with the domestic‑content requirement without compromising on quality.

Frequently asked questions

Q1: Can the DCTC be claimed for equipment purchased before the IRA was enacted? A: No. Only property placed in service after 1 January 2023 qualifies for the credit.

Q2: Is there a minimum investment amount to be eligible? A: The Treasury does not set a minimum, but the credit is only meaningful for projects with a qualified investment of at least US$500 000, given the per‑employee cap.

Q3: How does the credit interact with the Research & Development (R&D) tax credit? A: The DCTC is a separate credit and can be claimed in addition to the R&D credit, provided the same expenses are not double‑counted.

Q4: What happens if a component’s origin cannot be verified? A: The component must be excluded from the domestic‑content calculation, which may reduce the overall credit. In some cases, a reasonable‑certainty approach is permitted if the supplier provides a sworn statement of US origin.